Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors inside the central anxious program, conolidine modulates alternate molecular targets. A Science Innovations study found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://pukkabookmarks.com/story20890353/conolidin-to-replace-traditional-painkillers-options